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Summary
Background Randomised trials have shown that alteplase improves the odds of a good outcome when delivered within 
4·5 h of acute ischaemic stroke. However, alteplase also increases the risk of intracerebral haemorrhage; we aimed to 
determine the proportional and absolute eff ects of alteplase on the risks of intracerebral haemorrhage, mortality, and 
functional impairment in diff erent types of patients.
Methods We used individual patient data from the Stroke Thrombolysis Trialists’ (STT) meta-analysis of randomised 
trials of alteplase versus placebo (or untreated control) in patients with acute ischaemic stroke. We prespecifi ed 
assessment of three classifi cations of intracerebral haemorrhage: type 2 parenchymal haemorrhage within 7 days; 
Safe Implementation of Thrombolysis in Stroke Monitoring Study’s (SITS-MOST) haemorrhage within 24–36 h 
(type 2 parenchymal haemorrhage with a deterioration of at least 4 points on National Institutes of Health Stroke 
Scale [NIHSS]); and fatal intracerebral haemorrhage within 7 days. We used logistic regression, stratifi ed by trial, to 
model the log odds of intracerebral haemorrhage on allocation to alteplase, treatment delay, age, and stroke severity. 
We did exploratory analyses to assess mortality after intracerebral haemorrhage and examine the absolute risks of 
intracerebral haemorrhage in the context of functional outcome at 90–180 days.
Findings Data were available from 6756 participants in the nine trials of intravenous alteplase versus control. Alteplase 
increased the odds of type 2 parenchymal haemorrhage (occurring in 231 [6·8%] of 3391 patients allocated alteplase 
vs 44 [1·3%] of 3365 patients allocated control; odds ratio [OR] 5·55 [95% CI 4·01–7·70]; absolute excess 5·5% 
[4·6–6·4]); of SITS-MOST haemorrhage (124 [3·7%] of 3391 vs 19 [0·6%] of 3365; OR 6·67 [4·11–10·84]; absolute 
excess 3·1% [2·4–3·8]); and of fatal intracerebral haemorrhage (91 [2·7%] of 3391 vs 13 [0·4%] of 3365; OR 7·14 
[3·98–12·79]; absolute excess 2·3% [1·7–2·9]). However defi ned, the proportional increase in intracerebral 
haemorrhage was similar irrespective of treatment delay, age, or baseline stroke severity, but the absolute excess risk 
of intracerebral haemorrhage increased with increasing stroke severity: for SITS-MOST intracerebral haemorrhage 
the absolute excess risk ranged from 1·5% (0·8–2·6%) for strokes with NIHSS 0–4 to 3·7% (2·1–6·3%) for NIHSS 22 
or more (p=0·0101). For patients treated within 4·5 h, the absolute increase in the proportion (6·8% [4·0% to 9·5%]) 
achieving a modifi ed Rankin Scale of 0 or 1 (excellent outcome) exceeded the absolute increase in risk of fatal 
intracerebral haemorrhage (2·2% [1·5% to 3·0%]) and the increased risk of any death within 90 days (0·9% [–1·4% 
to 3·2%]).
Interpretation Among patients given alteplase, the net outcome is predicted both by time to treatment (with faster 
time increasing the proportion achieving an excellent outcome) and stroke severity (with a more severe stroke 
increasing the absolute risk of intracerebral haemorrhage). Although, within 4·5 h of stroke, the probability of 
achieving an excellent outcome with alteplase treatment exceeds the risk of death, early treatment is especially 
important for patients with severe stroke.
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Introduction
The Stroke Thrombolysis Trialists’ (STT) Collaboration has 
previously shown in a meta-analysis1 of individual patient 
data from nine trials of alteplase versus placebo (or 
untreated control) that alteplase signifi cantly improves the 
odds of an excellent outcome (ie, a modifi ed Rankin Scale 
[mRS] of 0 or 1) when delivered within 4·5 h of the onset of 
ischaemic stroke. However, alteplase increases the risk of 
intracerebral haemorrhage within 48 h of administration,1 
and variations in the absolute risks of such haemorrhage 
according to clinical presentation (eg, stroke severity) 
might aff ect the long-term outcome. In the past 2 years, 
several publications have drawn attention to the scarcity of 
reliable information about the hazards of alteplase and 
how they relate to benefi ts in diff erent groups of patients, 
particularly patients presenting later than 3 h after stroke 
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onset.2,3 In the UK, the Medicines and Healthcare Products 
Regulatory Agency Expert Working Group considered both 
the STT Collaboration’s published analyses and, in 
confi dence, unpublished analyses of the eff ects of alteplase 
on intracerebral haemorrhage as part of its review of the 
market authorisation for alteplase in acute ischaemic 
stroke.4
Because strong associations exist between prognostic 
variables in the trials included in the STT database 
(eg, patients treated earlier tended to be older and to have 
had more severe strokes), an assessment of benefi t and 
harm can only be done reliably using multivariable 
models applied to individual participant data. The STT’s 
protocol5 outlined secondary analyses that were to be 
done in addition to the main analysis.1 The aim of this 
Article is to describe the results of secondary analyses 
assessing the proportional and absolute eff ects of 
alteplase on the risk of intracerebral haemorrhage, 
mortality, and functional impairment in patients with 
diff erent characteristics. We also explore how such 
variations might aff ect the net eff ects of alteplase by 
90–180 days after stroke.
Methods
Study design
The methods for the meta-analysis planned by the Stroke 
Thrombolysis Trialists’ (STT) Collaboration have been 
described in detail in the protocol5 and in the main report 
of the primary analysis.1 Briefl y, we sought individual 
patient data from all completed randomised phase 3 
trials of intravenous alteplase in patients with acute 
ischaemic stroke. We identifi ed potentially eligible trials 
for our analysis from a systematic review6 of trials of 
thrombolysis that had been updated in 2013 and from 
active trialists and the manufacturer of alteplase used in 
all participating trials (Boehringer Ingelheim, Ingelheim, 
Germany).5 We analysed participants in the group to 
which they were randomly assigned (intention to treat).
Outcomes
The main outcome of interest in this secondary analysis 
was intracerebral haemorrhage, which was defi ned in 
three ways: type 2 parenchymal haemorrhage by 7 days 
after randomisation; Safe Implementation of Thrombolysis 
in Stroke Monitoring Study’s (SITS-MOST) haemorrhage;7 
or fatal intracerebral haemorrhage within 7 days.
Type 2 parenchymal haemorrhage by 7 days after 
randomisation was defi ned as dense blood clots 
exceeding 30% of the infarct volume with a signifi cant 
space-occupying eff ect seen on brain imaging, whether 
within or remote from the infarct.8 For patients from the 
Third International Stroke Trial (IST-3),9 in which type 2 
parenchymal haemorrhage defi ned solely on radiological 
fi ndings was not a prespecifi ed secondary outcome, we 
recorded a type 2 parenchymal haemorrhage if there was 
a report from the IST-3 blinded CT-reading panel of 
signifi cant brain parenchymal haemorrhage, local or 
remote from the infarct, or signifi cant diff use haemor-
rhagic transformation of an infarct on brain imaging.
SITS-MOST haemorrhage7 was defi ned as type 2 
parenchymal haemorrhage on imaging with an increase 
in the National Institutes of Health Stroke Scale 
(NIHSS) of 4 points or more from baseline (or the 
lowest point in the fi rst 24 h) or that led to death within 
36 h of treatment. In IST-3, we approximated the 
SITS-MOST defi nition by the occurrence within 24 h of 
clinically signifi cant deterioration or death, together 
with evidence of either signifi cant brain parenchymal 
haemorrhage (local or distant from the infarct) or 
signifi cant haemorrhagic transformation of an infarct 
on brain imaging, which, in the judgment of the blinded 
adjudication panel, was likely to have worsened mass 
eff ect or contributed to the burden of brain damage.9
Fatal intracerebral haemorrhage was defi ned as type 2 
parenchymal haemorrhage (or its approximation in 
IST-3) confi rmed with imaging (or at autopsy) and death 
within 7 days of randomisation.
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Research in context
Evidence before this study
Meta-analyses have previously shown that alteplase increases 
the risk of intracerebral haemorrhage, but the extent to which 
the absolute excess risk diff ers by haemorrhage type, stroke 
severity, age, or treatment delay was uncertain, as was the 
balance between the risk of intracerebral haemorrhage and 
treatment benefi t in diff erent patients. We used individual 
participant data from the Stroke Thrombolysis Trialists’ (STT) 
meta-analysis of nine trials of alteplase versus control to do 
secondary analyses of the available evidence.
Added value of this study
This study provides estimates of symptomatic intracerebral 
haemorrhage risk, and benefi ts due to alteplase, in patients 
grouped by stroke severity, age, and treatment delay. With the 
individual participant data, we were able to adjust for complex 
intercorrelations between variables to produce reliable 
estimates of absolute treatment eff ects.
Implications of all the available evidence
The absolute benefi ts of alteplase decrease with treatment 
delay, and the absolute harms due to alteplase (from 
intracranial haemorrhage) increase with stroke severity. When 
delivered within 4·5 h, the proportion of patients with a good 
outcome exceeds that of patients dying from intracranial 
haemorrhage. However, because the risk of haemorrhage is 
highest in patients with the most severe stroke, prompt 
treatment of these patients is important. These absolute risk 
estimates will be useful to communicate the eff ects of alteplase 
to patients, families, and clinicians.
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The timing of brain imaging to detect intracerebral 
haemorrhage varied slightly across the participating 
trials. The protocol of each trial mandated imaging at 
about 24 h after randomisation and additional brain 
imaging if neurological deterioration occurred. Further 
routine brain imaging was done at 3–5 days in the 
Echoplanar Imaging Thrombolytic Evaluation Trial 
(EPITHET);10 at 1 week in the National Institutes of 
Neurological Diseases and Stroke (NINDS) A and B11 and 
in the European Cooperative Acute Stroke Study (ECASS) 
I, II, and III;8,12,13 and at 23–37 days in the Alteplase 
Thrombolysis for Acute Non-interventional Therapy in 
Ischemic Stroke (ATLANTIS) A and B.14,15
Analyses of the eff ect of alteplase on death from all 
causes within 90 days, both overall and when separated 
by a period of follow-up and treatment delay, have been 
published previously.1 In post-hoc analyses of mortality 
for this analysis, we subdivided deaths into those that 
were preceded by clinically signifi cant intracerebral 
haemor rhage (defi ned as fatal intracerebral haemorrhage 
within 7 days or death following SITS-MOST haemor-
rhage) and all other deaths.
We analysed the mRS to defi ne stroke outcome at 
3–6 months. We defi ned an excellent stroke outcome as 
mRS of 0–1 (ie, symptom free or residual symptoms with 
no loss of activity) and a very poor stroke outcome as 
mRS of 5–6 (ie, bed bound or dead) at 3–6 months. 
In IST-3, mRS was reported at 6 months rather than 
3 months. Therefore, for consistency between the 
previously published analyses of 90 day mortality and the 
odds ratios (OR) for mRS 0–5 versus 6 in this analysis, 
we made the assumption that IST-3 patients who died 
between 91 days and 6 months (125 [4%] of 3035 IST-3 
participants) had an mRS of 5 at 90 days.1
Statistical analysis
We used logistic regression, stratifi ed by trial, to model 
the common linear dependence of the log odds of 
intracerebral haemorrhage on treatment allocation 
(alteplase or control), treatment delay, age, baseline 
NINDS A11 NINDS B11 ECASS I8 ECASS II12 ATLANTIS A15 ATLANTIS B14 ECASS III13 EPITHET10 IST-39 Total
Patients 291 333 620 800 142 613 821 101 3035 6756
Alteplase 144 (49%) 168 (50%) 313 (50%) 409 (51%) 71 (50%) 301 (49%) 418 (51%) 52 (51%) 1515 (50%) 3391 (50%)
Control 147 (51%) 165 (50%) 307 (50%) 391 (49%) 71 (50%) 312 (51%) 403 (49%) 49 (49%) 1520 (50%) 3365 (50%)
Treatment delay (h) 2·0 (0·6) 2·0 (0·6) 4·4 (1·1) 4·3 (1·1) 4·3 (1·1) 4·4 (0·8) 4·0 (0·4) 4·9 (0·8) 4·2 (1·2) 4·0 (1·2)
>0 to ≤3 290 (>99%) 333 (100%) 87 (14%) 158 (20%) 22 (15%) 39 (6%) ·· ·· 620 (20%) 1549 (23%)
>3 to ≤4·5 1 (<1%) ·· 233 (38%) 265 (33%) 53 (37%) 249 (41%) 788 (96%) 31 (31%) 1148 (38%) 2768 (41%)
>4·5 ·· ·· 295 (48%) 370 (46%) 67 (47%) 321 (52%) 6 (1%) 69 (68%) 1266 (42%) 2394 (35%)
Missing ·· ·· 5 (1%) 7 (1%) ·· 4 (1%) 27 (3%) 1 (1%) 1 (<1%) 45 (1%)
Age (years) 66 (11) 68 (12) 65 (12) 66 (11) 66 (13) 66 (11) 65 (12) 72 (13) 77 (12) 71 (13)
≤80 279 (96%) 289 (87%) 615 (>99%) 792 (99%) 142 (100%) 608 (>99%) 805 (98%) 76 (75%) 1418 (47%) 5024 (74%)
>80 12 (4%) 44 (13%) 5 (1%) 8 (1%) ·· 3 (<1%) 15 (2%) 25 (25%) 1617 (53%) 1729 (26%)
Missing ·· ·· ·· ·· ·· 2 (<1%) 1 (<1%) ·· ·· 3 (<1%)
Stroke severity (NIHSS) 14 (7) 15 (7) 12 (6) 12 (6) 13 (7) 11 (6) 10 (5) 13 (6) 12 (7) 12 (7)
>0 to ≤4 16 (5%) 13 (4%) 34 (5%) 47 (6%) 10 (7%) 47 (8%) 98 (12%) 1 (1%) 400 (13%) 666 (10%)
>4 to ≤10 78 (27%) 98 (29%) 189 (30%) 339 (42%) 57 (40%) 279 (46%) 389 (47%) 40 (40%) 1064 (35%) 2533 (37%)
>10 to ≤15 68 (23%) 63 (19%) 183 (30%) 232 (29%) 28 (20%) 128 (21%) 163 (20%) 22 (22%) 601 (20%) 1488 (22%)
>15 to ≤21 76 (26%) 78 (23%) 146 (24%) 113 (14%) 25 (18%) 106 (17%) 142 (17%) 29 (29%) 618 (20%) 1333 (20%)
>21 45 (15%) 74 (22%) 28 (5%) 43 (5%) 20 (14%) 33 (5%) 18 (2%) 9 (9%) 352 (12%) 622 (9%)
Missing 8 (3%) 7 (2%) 40 (6%) 26 (3%) 2 (1%) 20 (3%) 11 (1%) ·· ··* 114 (2%)
Women 120 (41%) 142 (43%) 231 (37%) 331 (41%) 45 (32%) 250 (41%) 325 (40%) 43 (43%) 1570 (52%) 3057 (45%)
History of hypertension 188 (65%) 220 (66%) 258 (42%) 412 (52%) 87 (61%) 364 (59%) 514 (63%) 71 (70%) 1954 (64%) 4068 (60%)
History of stroke 49 (17%) 34 (10%) 83 (13%) 158 (20%) 31 (22%) 89 (15%) 89 (11%) 11 (11%) 699 (23%) 1243 (18%)
History of diabetes mellitus 64 (22%) 67 (20%) 81 (13%) 169 (21%) 27 (19%) 130 (21%) 129 (16%) 23 (23%) 388 (13%) 1078 (16%)
History of atrial fi brillation 55 (19%) 60 (18%) 113 (18%) 188 (24%) 37 (26%) 97 (16%) 108 (13%) 42 (42%) 914 (30%) 1614 (24%)
Antiplatelet use 78 (27%) 93 (28%) 87 (14%) 196 (25%) 59 (42%) 211 (34%) 201 (24%) 30 (30%) 1306 (43%) 2261 (33%)
Weight (kg) 78 (17) 78 (19) 74 (12) 75 (14) 80 (20) 79 (18) 78 (15) 75 (19) 72 (15) 75 (16)
Systolic blood pressure (mm Hg) 154 (21) 152 (21) 154 (23) 152 (21) 152 (24) 152 (21) 153 (21) 148 (19) 155 (24) 154 (22)
Diastolic blood pressure (mm Hg) 85 (13) 85 (14) 87 (13) 84 (13) 81 (14) 82 (14) 84 (14) 78 (13) 82 (15) 83 (14)
Data are n (%) or mean (SD). NINDS=National Institute of Neurological Disorders and Stroke. ECASS=European Cooperative Acute Stroke Study. ATLANTIS=Alteplase Thrombolysis for Acute Noninterventional 
Therapy in Ischemic Stroke. EPITHET=Echoplanar Imaging Thrombolytic Evaluation Trial. IST=International Stroke Trial. NIHSS=National Institutes of Health Stroke Scale. *In IST-3, 244 patients had their baseline 
NIHSS score predicted from other measurements recorded at their baseline assessment. With exclusion of these patients, the numbers of IST-3 patients in each NIHSS categories would be 385, 972, 531, 559, 
and 344, respectively.
Table 1: Baseline characteristics of patients in participating trials
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stroke severity (measured with the NIHSS), and 
interactions between treatment allocation and each of 
these other baseline covariates. Treatment delay, age, and 
stroke severity were all analysed as linear variables. 
In addition to such continuous analyses, we also used 
regression models that analysed each baseline covariate 
in pre defi ned categories of treatment delay (≤3·0 h, 
>3 to ≤4·5 h, and >4·5 h), age (≤80 years and >80 years), 
and stroke severity (NIHSS ≤4, 5–10, 11–15, 16–21, and 
≥22). We imputed missing 6 month mRS data in IST-3 
from 7 day assessments with an algorithm that worked 
well in patients who had both measurements.5 We 
assessed whether treatment delay, age, stroke severity, or 
trial modifi ed (individually or jointly) the overall eff ect of 
alteplase on particular outcomes on the basis of the 
signifi cance of the relevant treatment interactions in the 
likelihood ratio tests (ie, through comparison of minus 
twice the log-likelihood statistic between appropriate 
nested models). We used trial-by-treatment interactions 
to assess whether important diff erences in the odds of 
intracerebral haemorrhage with alteplase existed between 
the nine trials, and between IST-3 (with untreated-
control) and the other (placebo-controlled) trials 
combined.
We calculated Kaplan-Meier cumulative mortality 
curves during the fi rst 90 days for patients allocated to 
the alteplase and control groups (crudely pooling across 
all trials). Subsequently, we used trial-stratifi ed Cox 
regression to estimate the mortality hazard ratio [HR] 
within 90 days for deaths preceded by clinically 
signifi cant intracerebral haemor rhage and for all other 
deaths, with the time to event either at death, or censored 
at 90 days.
Stroke severity and treatment delay are both important 
determinants of stroke outcome for patients given 
alteplase. However, stroke severity and treatment delay 
were correlated in the included trials.1 Therefore, to 
prevent treatment delay from confounding the observed 
mRS distribution when treated patients were subdivided 
by their baseline stroke severity (NIHSS ≤4, 5–10, 11–15, 
16–21, and ≥22), we compared, for each baseline NIHSS 
group, the observed mRS distribution for control patients 
with the expected distribution if given alteplase within 
3 h or within 4·5 h. We obtained this expected distribution 
by applying the overall ORs for each mRS dichotomy (ie, 
mRS 0 vs 1–6 and mRS 0–1 vs 2–6) within a given time 
window (≤4·5 h, <3 h, or 3–4·5 h) to the observed mRS 
PH-2
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Figure 1: Eff ect of alteplase treatment within 7 days on type 2 parenchymal haemorrhage, SITS-MOST 
haemorrhage, and fatal intracerebral haemorrhage
ICH=intracerebral haemorrhage. PH-2=parenchymal haemorrhage type 2. SITS-MOST=Safe Implementation of 
Thrombolysis in Stroke Monitoring Study. *Estimated from a trial-stratifi ed logistic regression model adjusted 
only for treatment allocation.
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≤3 h
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Figure 2: Eff ect of alteplase on SITS-MOST intracerebral haemorrhage at 24–36 h by time to treatment, age, and stroke severity
For each of the three baseline characteristics shown, the OR subgroup estimates are derived from a single trial-stratifi ed logistic regression model that allows for separate estimation of the OR in each 
of the subgroups after adjustment for the other two baseline characteristics (but not possible interactions with those characteristics). The overall eff ect (indicated by the open diamond) is the 
trial-stratifi ed logistic regression estimate adjusted only for treatment allocation. The absolute excess risk (95% CI) for each subgroup is estimated by application of the OR seen among all randomly 
assigned patients (or its confi dence limits) to the mean expected risk in control-allocated patients for that subgroup (estimated from a logistic regression model among all participants adjusted for 
trial, treatment allocation, the subgroup of interest, and mean levels of the other two baseline characteristics). SITS-MOST=Safe Implementation of Thrombolysis in Stroke Monitoring Study. 
OR=odds ratio. NIHSS=National Institutes of Health Stroke Scale. 
Articles
www.thelancet.com/neurology   Vol 15   August 2016 929
distribution at 3–6 months in control-allocated patients. 
Similarly, the estimates of absolute excess risk subdivided 
by a given characteristic (treatment delay, age, or stroke 
severity) were obtained by applying the overall OR 
estimates (and their 95% CIs) to the control rates that 
would have been expected for that subgroup had the 
mean levels of the other two characteristics applied.
All estimates of treatment eff ect are provided with their 
95% CIs with p values that are deemed conventionally 
signifi cant, without allowance for multiple testing, at the 
5% signifi cance level. We did the analyses with SAS 
(version 9.3) and R (version 2.11.1).
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The secretariat had full access to all the data and had fi nal 
responsibility for the decision to submit for publication.
Results
Data were available from 6756 participants in nine trials 
of intravenous alteplase versus control (table). Baseline 
data on treatment delay, age, and NIHSS were complete 
for almost all participants (6602 (98%) of 6756 participants). 
Individual participant data were sought from an 
additional fi ve trials16–20 involving 270 participants, which 
reported a total of 18 patients with intracerebral haem-
orrhage (11 patients received alteplase and seven from the 
control), but were either not available or, in one case,18 the 
authors could not be contacted.
Overall, 275 (4·1%) of 6756 participants had a type 2 
parenchymal haemorrhage within 7 days of treatment, of 
which 104 (38%) were fatal within 7 days (91 [39%] of 
231 participants in the alteplase group vs 13 [30%] of 44 in 
the control group). 143 (52%) of these haemorrhages 
were SITS-MOST haemorrhages (50 [40%] of 124 vs nine 
[47%] of 19), of which 59 (41%) were fatal within 7 days. 
Alteplase increased the odds of intracerebral haem-
orrhage by a factor of about six to seven, depending on 
the defi nition used: type 2 parenchymal haemorrhage 
(231 [6·8%] of 3391 vs 44 [1·3%] of 3365; OR 5·55, 95% CI 
4·01–7·70; absolute excess 5·5% [4·6–6·4]); SITS-MOST 
haemorrhage (124 [3·7%] of 3391 vs 19 [0·6%] of 3365; 
OR 6·67, 4·11–10·84; absolute excess 3·1% [2·4–3·8]); 
and fatal intracerebral haemorrhage within 7 days 
(91 [2·7%] of 3391 vs 13 [0·4%] of 3365; OR 7·14, 
3·98–12·79; absolute excess 2·3% [1·7–2·9%]; fi gure 1). 
These ORs were similar after adjusting for baseline 
variables (age, sex, treatment delay, stroke severity, 
previous stroke, or transient ischaemic attack, previous 
diabetes, antiplatelet use, weight, and systolic blood 
pressure at randomisation; data not shown). We found 
no evidence that the ORs for any of the defi nitions of 
intracerebral haemorrhage diff ered between trials, or 
between IST-3 (which was untreated control) and the 
eight placebo-controlled trials (all heterogeneity 
p values >0·05; appendix p 2). The proportion of patients 
with type 2 parenchymal haemorrhage who died by 
7 days was also similar in IST-3 (62 [39%] of 159 patients) 
and in the other eight placebo-controlled trials (42 [36%] 
of 116).
For each type of intracerebral haemorrhage, the 
proportional eff ects of alteplase were similar irrespective 
of time to treatment, age, or stroke severity (appendix 
pp 3–5; all p values for interaction >0·05). The estimated 
absolute excess risks were similar irrespective of time to 
treatment and age, but increased with increasing stroke 
severity for type 2 parenchymal haemorrhage (p<0·0001; 
appendix p 6), fatal intracerebral haemorrhage 
(p=0·0002; appendix p 7), and SITS-MOST haemorrhage 
(p=0·0101; fi gure 2). For SITS-MOST intracerebral 
haemorrhages (ie, clinically signifi cant bleeds in which 
there was both radiological evidence of bleeding and 
worsening symptoms within 36 h of treatment), the 
absolute excess risk over control increased from 1·5% 
(95% CI 0·8–2·6%) in patients with mild strokes 
(baseline NIHSS 0–4) to 3·7% (2·1–6·3%) in patients 
with the most severe strokes (NIHSS ≥22; fi gure 2).
Cause of death was not widely available in participating 
trials, but we did exploratory analyses to assess the risk of 
death preceded by clinically signifi cant intracerebral 
haemorrhage and of all other deaths at 90 days. Among all 






















































HR 8·52 (95% CI 4·89–14·82); p<0·0001
HR 0·92 (95% CI 0·82–1·04); p=0·19
Figure 3: The eff ect of alteplase on deaths after clinically signifi cant ICH,* and 
all other deaths, within 90 days
Hazard ratio (HR) estimated by Cox proportional hazards regression stratifi ed by trial, 
with adjustment for treatment allocation. ICH=intracerebral haemorrhage. SITS-
MOST=Safe Implementation of Thrombolysis in Stroke Monitoring Study. *Fatal 
haemorrhage within 7 days or death after SITS-MOST haemorrhage. See Online for appendix
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associated with a signifi cant increase in the risk of death 
preceded by clinically signifi cant intracerebral haem-
orrhage within 90 days (118 [3·5%] of 3391 vs 14 [0·4%] of 
3365; HR 8·52, 95% CI 4·89–14·82; fi gure 3). However, 
deaths were off set by non-signifi cantly fewer deaths among 
people who had not had a haemorrhage (490 [14·5%] of 
3391 vs 542 [16·1%] of 3365; HR 0·92, 0·82–1·04; fi gure 3). 
An analysis that defi ned clinically signifi cant haemorrhage 
by the radiological appearance of a type 2 parenchymal 
haemorrhage, rather than by the SITS-MOST defi nition, 
gave similar results (appendix p 10).
Because the estimated absolute excess risk of 
intracerebral haemorrhage increased according to the 
fi ve baseline categories of stroke severity, we assessed the 
eff ect of this increase on the expected distribution of mRS 
scores at 90 days in all patients treated within 4·5 h (mean, 
at 3 h and 20 min) by applying the OR for each mRS 
transition to the control population (fi gure 4). Among 
patients with the mildest strokes (NIHSS 0–4), alteplase 
within 4·5 h would be expected to result in an absolute 
increase in excellent outcome of 8·0% (95% CI 4·5 to 11·1), 
and to reduce the absolute risk of very poor outcome by 
0·1% (–0·6 to 0·8; consisting of a 0·3% absolute reduction 
in severe disability [mRS 5] and a 0·2% absolute increase 
in death). For the most severe strokes (NIHSS ≥22), 
alteplase would be expected to result in an absolute 
increase in excellent outcome of 1·0% (0·5 to 1·5), and to 
reduce the absolute risk of very poor outcome by 0·6% 
(–2·3 to 4·1; consisting of a 2·8% reduction in severe 
disability and a 2·1% absolute increase in death. Overall, 
for patients treated within 4·5 h, the absolute increase in 
the proportion of patients achieving a modifi ed Rankin 
Scale of 0 or 1 (6·8%, 4·0 to 9·5) exceeded the absolute 
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Figure 4: Estimated proportion of patients in each mRS score category with or without alteplase, according to stroke severity at baseline
An mRS of 0–1 indicates an excellent outcome: survival symptom free or with residual symptoms with no loss of activity. mRS 5–6 indicates bed bound or dead at 
3–6 months. In IST-3, 125 (4·1%) of 3035 patients died between 3 and 6 months. For comparability of mRS 6 between IST-3 and the other trials (which assessed mRS 
scores at 3 months), these patients were reassigned an mRS of 5 for this analysis. NIHSS=National Institutes of Health Stroke Scale. mRS=modifi ed Rankin Scale. 
IST-3=Third International Stroke Trial.
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1·5 to 3·0) and the absolute increased risk of death within 
90 days (0·9%, –1·4 to 3·2).
Discussion
In the nine trials included in the analysis, alteplase 
increased the odds of intracerebral haemorrhage within 
the fi rst 7 days by about six to seven times compared with 
control treatment. The proportional increase in the odds 
was similar irrespective of treatment delay, age, and 
stroke severity at baseline. In these trials, the underlying 
risk of intracerebral haemorrhage without alteplase 
increased with stroke severity, which is consistent with a 
systematic review of 55 observational studies in which 
each 1 point increment in the NIHSS was associated with 
an 8% (95% CI 6–11) increase in the odds of intracerebral 
haemorrhage (p<0·001).21 In the absence of heterogeneity 
of the OR for haemorrhage, the absolute excess risk of 
intracerebral haemorrhage was higher in patients with 
the severest strokes. Overall, alteplase resulted in a 2·3% 
absolute excess of fatal intracerebral haemorrhage during 
the fi rst week (fi gure 1). After the fi rst week, deaths 
preceded by intracerebral haemorrhage remained 
elevated in patients given alteplase (fi gure 3), perhaps 
because of disorders associated with chronic immobility 
(eg, pneumonia). By contrast, during the fi rst 90 days, 
non-signifi cantly fewer other deaths occurred in patients 
in the alteplase group than in the control group, perhaps 
because of the benefi cial eff ects of alteplase on functional 
outcome (fi gures 3, 4).
Taken together, the present analyses and our previous 
report1 show that, when given within 4·5 h, alteplase is 
associated with an early hazard due to intracerebral 
haemorrhage but a later benefi t in terms of less disability. 
This study raises the hypothesis that alteplase reduces 
mortality risk in patients in whom it does not cause 
intracerebral haemorrhage. This pattern is analogous to 
that of many surgical procedures (eg, carotid 
endarterectomy) that are associated with an early hazard 
followed by a later survival benefi t,22,23 and for which the 
balance of hazard and benefi t in particular types of 
patients determines their net clinical outcome.
The net eff ects of alteplase in particular types of 
patients are best represented by the predicted shift in the 
distribution of the mRS in patients allocated to alteplase 
or control. Our previous analyses showed that the 
benefi ts of alteplase diminish with increasing treatment 
delay, whereas the present analyses suggest that the 
absolute excess risk of intracerebral haemorrhage 
increases with stroke severity. Our exploratory analyses 
suggest that these two variables help determine the net 
eff ects of alteplase in particular patients. These variables 
might help to explain the non-signifi cantly larger relative 
increase in 90 day mortality in patients treated later than 
3 h in our previous report.1 The patterns could be due to 
the shifting balance between an early increase in 
mortality from intracerebral haemorrhage (which is of 
similar magnitude irrespective of delay) and a reduced 
mortality due to salvaged brain tissue in patients treated 
early, with the magnitude of this benefi t diminishing as 
delay increases (ie, time is brain).
There is a need for improved representations of the 
benefi ts and risks of alteplase, building on those 
developed previously,24–27 to better equip clinicians in 
discussions with patients and their family members. 
Established approaches of representing mRS (fi gure 4) 
have the inherent limitation that they do not directly 
represent the additional risks of fatal intracerebral 
haemorrhage. Figure 5 is an example of a possible 
representation of the expected eff ects of alteplase on the 
distribution of mRS scores, subdivided by stroke severity. 
The results of previous trials have shown that intra-
arterial thrombectomy, when given to patients who have 
already received intravenous thrombolysis, leads to 
improved outcomes28–32 in patients with large artery 
ischaemic stroke and documented proximal arterial 
occlusion. This combination might help to improve the 
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0–1 2 3 4 5 6mRS:
Figure 5: Expected stroke outcome at 3–6 months for diff erent groups of patients
mRS 0–1 indicates an excellent outcome: survival symptom free or residual symptoms with no loss of activity. mRS 
5–6 indicates bed bound or dead at 3–6 months. Each 10 × 10 grid represents 100 hypothetical patients who have 
had a stroke with severity 0−4 NIHSS points, 5−15 points, or 16 or more points. mRS=modifi ed Rankin Scale. 
NIHSS=National Institutes of Health Stroke Scale. *Death within 7 days and after a type 2 parenchymal haemorrhage.
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improved salvage of brain tissue. Alternatively, this ratio 
might be improved by reducing the risk of intracerebral 
haemorrhage with intravenous thrombolytic therapy—eg, 
by use of tenecteplase as an alternative to alteplase,33,34 use 
of a reduced dose of alteplase (0·6 mg/kg),35 or by targeting 
thrombolysis on the basis of neuroimaging appearances.36,37
Although our analyses provide a general guide to the 
eff ects of alteplase in diff erent types of patients, our 
study had several limitations. First, and most importantly, 
despite having access to individual participant data from 
nine trials in almost 7000 patients with acute ischaemic 
stroke, the number of outcomes with which to examine 
treatment eff ects in diff erent patient subgroups was 
small.38 Although we recognise the need to provide 
improved information for doctors and patients, we 
believe that treatment decisions need to take account of 
both statistical uncertainty and the possibility that 
diff erent patients and their families might reach diff erent 
decisions when presented with the same data on expected 
outcomes. The second limitation was that the methods 
used by IST-3 diff ered in several respects to those of the 
other trials. IST-3 did not have a placebo control, which 
increased the potential for biased reporting; for example, 
a greater tendency to investigate possible intracerebral 
haemorrhage in the alteplase group than in the control 
group. However, alteplase increased the odds of 
intracerebral haemorrhage to a similar extent in IST-3 
and the other trials (appendix), suggesting that any bias 
due to the open nature of IST-3 was small. IST-3 also did 
not record type 2 parenchymal or SITS-MOST 
haemorrhages, but defi ned equivalent categories. In the 
future, any such limitations caused by diff erent 
symptomatic haemorrhage defi nitions and classifi cations 
could be mitigated by the use of the Heidelberg 
classifi cation of intracerebral bleeding events.39
A third limitation was that we did not have data on cause 
of death available, but could only examine the eff ects of 
alteplase on deaths that followed a haemorrhage. However, 
our data strongly suggest that most early deaths after a 
type 2 parenchymal haemorrhage were likely to be due to 
the haemorrhage. In particular, the increased risk of death 
from any cause by 7 days (absolute excess 2·2%)1 is almost 
identical to the increased risk of fatal ICH within 7 days 
(2·3%; fi gure 1). Additionally, death preceded by clinically 
signifi cant haemorrhage remained elevated after the fi rst 
week (fi gure 3). The most likely explanation for these 
observations is that haemorrhage led to death in almost all 
such cases (either directly or after withdrawal of medical 
intervention), because the alternative explanation—that 
patients given alteplase were at least seven times more 
likely than control patients to die from causes unrelated to 
the bleed—seems highly implausible in view of their 
similar prognostic scores at randomisation and the 
absence of any other known hazard of alteplase.
Finally, we were restricted in the extent to which we 
could assess the eff ect of other potential risk factors, 
such as blood glucose and blood pressure control, that 
have previously been associated with increased bleeding 
risk after alteplase administration, and we could not 
assess the eff ects of alteplase on less severe intracerebral 
haemorrhage because the requisite data were not 
consistently available.
Although alteplase increases the early risk of 
haemorrhagic stroke, when given within 4·5 h of acute 
ischaemic stroke the increased proportion of patients with 
an excellent outcome exceeded the increased proportion 
dying from intracerebral haemorrhage. The greatest 
absolute risk of intracerebral haemorrhage after alteplase 
was in patients with the most severe strokes, among 
whom prompt treatment is essential to achieve benefi t.
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